How does 6976's PB Ratio compare to its peers?

6976 is good value based on its Price-To-Book Ratio (1.5x) compared to the peer average (5.1x).

How does 6976's PB Ratio compare vs other companies in the TW Biotechs Industry?

6976 is good value based on its Price-To-Book Ratio (1.5x) compared to the TW Biotechs industry average (3.7x).

What is 6976's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 6976's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 6976 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 6976's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Acepodia TPEX:6976 Stock Report

Last Price

NT$17.60

Market Cap

NT$10.1b

7D

1.4%

1Y

-48.5%

Updated

27 Dec, 2024

Data

Company Financials

Acepodia, Inc.

TPEX:6976 Stock Report

Market Cap: NT$10.1b

6976 Stock Overview

Operates as a clinical stage biotechnology company. More details

6976 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings have grown 3% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue (NT$17M)

My Notes

Capture your thoughts, links and company narrative

Acepodia, Inc. Competitors

Tanvex BioPharma

TWSE:6541

NT$10.2b

Lin BioScience

TPEX:6696

NT$10.5b

Mycenax Biotech

TPEX:4726

NT$8.9b

Medigen Vaccine Biologics

TPEX:6547

NT$12.4b

Price History & Performance

Summary of share price highs, lows and changes for Acepodia
Historical stock prices
Current Share Price	NT$17.60
52 Week High	NT$35.00
52 Week Low	NT$17.00
Beta	0
1 Month Change	-1.12%
3 Month Change	-26.05%
1 Year Change	-48.46%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-56.54%

Recent News & Updates

Recent updates

Shareholder Returns

	6976	TW Biotechs	TW Market
7D	1.4%	3.8%	1.3%
1Y	-48.5%	3.2%	27.5%

Return vs Industry: 6976 underperformed the TW Biotechs industry which returned 3.2% over the past year.

Return vs Market: 6976 underperformed the TW Market which returned 27.5% over the past year.

Price Volatility

Is 6976's price volatile compared to industry and market?
6976 volatility
6976 Average Weekly Movement	4.6%
Biotechs Industry Average Movement	4.5%
Market Average Movement	4.4%
10% most volatile stocks in TW Market	7.7%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 6976 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 6976's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Sonny Hsiao	www.acepodia.com

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies.

Acepodia, Inc. Fundamentals Summary

How do Acepodia's earnings and revenue compare to its market cap?
6976 fundamental statistics
Market cap	NT$10.06b
Earnings (TTM)	-NT$379.78m
Revenue (TTM)	NT$16.90m

595.2x

P/S Ratio

-26.5x

P/E Ratio

Is 6976 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6976 income statement (TTM)
Revenue	NT$16.90m
Cost of Revenue	NT$96.00k
Gross Profit	NT$16.81m
Other Expenses	NT$396.59m
Earnings	-NT$379.78m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.66
Gross Margin	99.43%
Net Profit Margin	-2,246.70%
Debt/Equity Ratio	0%

How did 6976 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 19:56
End of Day Share Price	2024/12/27 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Acepodia, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution